ArticleJournal of gastroenterology and hepatology2025
Phenotypic Differences and Clinical Outcomes of South Asian Children With IBD: A Singapore-Malaysia Study From the Asian PIBD Registry Network.
Article in Journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenotypic Differences and Clinical Outcomes of South Asian Children With IBD: A Singapore-Malaysia Study From the Asian PIBD Registry Network.Journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimExisting literature largely contrasts pediatric inflammatory bowel disease (PIBD) phenotypic differences and outcomes of South Asians (SAs) with Caucasians. No published comparative data exist between SAs and non-SAs within Asia-Pacific. We aim to validate these comparisons within Asia-Pacific, comparing SAs ("Indian," "Bangladeshi," "Nepali," "Pakistani," "Sri Lankan (Sinhalese/Tamil)," and "Maldivian") with their non-SA ("Chinese," "Malay," "Eurasian", or "Others") counterparts in the multiethnic populations of Singapore and Malaysia.
methodsClinical data from three centers in Singapore and Malaysia were compared, at baseline, 1-year (1YFU) and 5-year (5YFU) post-diagnosis, between SAs and non-SAs.
resultsBaseline, 1YFU, and 5YFU data were analyzed in 366, 260 (71.0%), and 127 (34.7%) patients, respectively. Compared with non-SAs, SAs were significantly older (10.2 vs. 9.1 years, p = 0.013), had less very early-onset disease (15.5% vs. 33.0%, p = 0.001), a shorter time from symptom onset to diagnosis (5.9 vs. 8.9 months, p = 0.024), less growth retardation (5.9% vs. 14.0%, p = 0.035), and less comorbid liver diseases (1.4% vs. 9.4%, p = 0.002). SAs with Crohn's disease had more symptomatic perianal disease (18.3% vs. 9.4%, p = 0.016) and less isolated ileal L1 disease (10.2% vs. 20.7%, p = 0.057). No significant differences in induction therapies, maintenance immunosuppression or remission rates at 1YFU were noted, but at 5YFU, SAs had significantly lower rates of clinical remission (SA = 68.3% vs. non-SA = 84.9%, p = 0.036), steroid-free remission (SA = 53.7% vs. non-SA = 73.3%, p = 0.043), and mucosal healing (calprotectin < 300 ug/g, 0.0% vs. 80.0%, p = 0.048).
conclusionsWe report unique phenotypic differences in SA and non-SA children with IBD. SAs had poorer long-term clinical outcomes, although short-term outcomes and therapy usage patterns were comparable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.